報價延遲最少15分鐘:2025/07/18 16:30 EDT
盤後時段
|
||||
|
4.6599 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.3
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.34/--
|
|
企業價值
8.46M
|
| 資產負債 |
|
每股賬面淨值
6.54
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
901
|
|
每股收益
0.00
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 16:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluatedby these tests to the drivers of coronary heart disease. |
